Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind trial of ravulizumab in complement-inhibitor-naïve adults with generalized myasthenia gravis
2018-003243-39Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myasthenia gravis (MG) comparing Ravulizumab with Placebo (2 arms). Primary endpoint: Change from baseline in MG-ADL total score. Started Mar 2019; status: completed.
02
Drugs
ravulizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2018-003243-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003243-39.